Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/04/2003US20030224362 Diagnosing alcoholism using presence of mutation in neuropeptide y gene; drug abuse; restriction fragment length polymorphisms; immunoassay
12/04/2003US20030224355 Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (alpha), HNF-1beta and HNF-4alpha
12/04/2003US20030224343 Kappa-PVIIA-related conotoxins as organ protectants
12/04/2003US20030224066 Polysaccharide extract of dioscorea sp. and an orally active pharmaceutical composition comprising the same
12/04/2003US20030224064 Anti-acne compositions and methods of use
12/04/2003US20030224063 Boron nitride particles coated with a silicone compound, and a fragrance molecularly entrapped within a cyclodextrin compound.
12/04/2003US20030224061 Oral composition with insulin-like activities and methods of use
12/04/2003US20030224059 Drug microparticles
12/04/2003US20030224058 Nanoparticulate fibrate formulations
12/04/2003US20030224057 Continuous method for preparing pharmaceutical granules
12/04/2003US20030224055 Compositions and processes for inhibiting gene expression using polynucleotides
12/04/2003US20030224053 Mixture of a polymer, an active ingredient and a solvent capable of being preserved within a container such that on release forms a peelable, water removable, agent-releasing film on the surface of skin
12/04/2003US20030224051 Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
12/04/2003US20030224050 Drug delivery system for sustained delivery of glipizide
12/04/2003US20030224049 Modified release formulation comprising an immediate and a slow release phase; all of the potassium clavulanate and up to 50% of the amoxicillin is in the immediate release phase
12/04/2003US20030224048 Nicotine-containing, controlled release composition and method
12/04/2003US20030224047 Levothyroxine compositions and methods
12/04/2003US20030224045 Combination immediate release sustained release levodopa/carbidopa dosage forms
12/04/2003US20030224043 Increasing the bioavailability of low solubility drugs, including a disintegrant and a porosigen promoting disintegrate in less than 10 minutes; high speed, drug delivery
12/04/2003US20030224042 Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
12/04/2003US20030224041 Emulsion formulations for hydrophilic active agents
12/04/2003US20030224040 Genomic screen for epigenetically silenced genes associated with cancer
12/04/2003US20030224039 Infusing at a low temperature below the phase transition of lipid; use for intravenous administration, inhalation administration; no toxic solvents, simple process; bactericides
12/04/2003US20030224037 An antitumor agent oxaliplatin in transferrins liposome ligand and polyoxyethylene glycol, improving the storage stability, detoxifying and inhibiting the side effect caused by therapeutic drug
12/04/2003US20030224035 A topical or transdermal drug delivery, including an inorganic hydroxide to neutralize the acids, increase the flux of the active agent through a body surface, increase the permeability
12/04/2003US20030224034 Personal care article and method for inhibiting attachment of yeast to skin
12/04/2003US20030224032 A substrate having a vapor deposited furanone compounds, covalent bonding through etherification or amination; protective coatings on medical equipment, seeds, fibrics, wool, hair, silk, cotton, chitin, collagen, animal
12/04/2003US20030224026 Dermatological or cosmetic composition which includes aromatic nitroxide compounds and their use
12/04/2003US20030224014 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
12/04/2003US20030224012 Identifying a BASB033 polypeptide or an antibody that is immunospecific for such polypeptide, present with in a biological sample form the animal suspected having meningococcus induced infections and meningitis
12/04/2003US20030224008 Novel uses for anti-malarial therapeutic agents
12/04/2003US20030224007 A protective protein in the form of vaccine, containing a polypeptide from a pro-region of a cathepsin L protease obtained from excretory/secretory products of newly excysted juvenile stages of Fasciola hepatical
12/04/2003US20030224006 A solid phase that is sustained by intermolecular interactions (hydrogen bonding) between two or more independent molecular entities, and at least one entity is a drug; improved drug solublity, stability, bioavailability
12/04/2003US20030223982 Enzymes in topical cosmetic or pharmaceutical compositions for the prevention of the ageing of human skin. In particular, the method prevents ageing effects caused by light. The method prevents the degradation of collagen within connective tissue
12/04/2003US20030223976 Control sequences of the human corin gene
12/04/2003US20030223972 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
12/04/2003US20030223964 Efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the
12/04/2003US20030223960 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
12/04/2003US20030223959 Diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological
12/04/2003US20030223958 Use of interleukin-19 to treat ovarian cancer
12/04/2003US20030223957 Bioerodible (biodegradable) polymers to address fundamental needs in ocular surgery including sealants and sealing methods, barriers to cellular adhesion and proliferation, and mechanical barriers. The present invention is directed to
12/04/2003US20030223956 Macromers having a backbone comprising a polymeric backbone comprising units with a 1,2- diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and other modifiers. When crosslinked, the macromers
12/04/2003US20030223953 Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof
12/04/2003US20030223941 Methods for modulating phototoxicity
12/04/2003US20030223937 Cationic quaternary ammonium heterocyclic compounds with steroid compound for respiratory system disorders
12/04/2003CA2784937A1 Ccr9 inhibitors and methods of use thereof
12/04/2003CA2771788A1 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
12/04/2003CA2493902A1 Decoy composition for treating and preventing inflammatory disease
12/04/2003CA2490062A1 Methods of treating bacterial infections and diseases associated therewith
12/04/2003CA2489145A1 Insulin-sensitizing agent
12/04/2003CA2487732A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003CA2487655A1 Methods and compositions for inhibiting hiv replication
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487279A1 Progestagenic dosage units
12/04/2003CA2487273A1 Agents and methods for the treatment of disorders associated with oxidative stress
12/04/2003CA2487268A1 Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
12/04/2003CA2487167A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003CA2487153A1 New formulation for the parenteral application of crobenetine
12/04/2003CA2487150A1 New formulation for parental application of sodium channel blocker
12/04/2003CA2487117A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection
12/04/2003CA2487112A1 Neuregulin based methods and compositions for treating cardiovascular diseases
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2487070A1 Aqueous fludarabine phosphate composition
12/04/2003CA2487017A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486967A1 Cardiolipin compositions their methods of preparation and use
12/04/2003CA2486966A1 Substituted quinazolinone compounds
12/04/2003CA2486962A1 Compounds
12/04/2003CA2486909A1 Compositions and method for transmucosal drug delivery and cryoprotection
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486753A1 8-fluorimidazo'1,2-a!pyridine derivatives as ligands for gaba receptors
12/04/2003CA2486750A1 Imidazo-pyridine derivatives as ligands for gaba receptors
12/04/2003CA2486716A1 Compositions and their uses for alleviating pain
12/04/2003CA2486709A1 Adduct of topiramate and tramadol hydrochloride and uses thereof
12/04/2003CA2486704A1 Anti-cancer formulation
12/04/2003CA2486665A1 Extraction of unmilled psyllium
12/04/2003CA2486651A1 Sulfone liver x-receptor modulators
12/04/2003CA2486644A1 Anilino liver x-receptor modulators
12/04/2003CA2486622A1 Aerosol drug inhibition of lung metastases
12/04/2003CA2486621A1 Induction and maintenance of tolerance to composite tissue allografts
12/04/2003CA2486620A1 Chimeric allograft tolerance induction, monitoring and maintenance
12/04/2003CA2486606A1 Antifungal effects of morinda citrifolia
12/04/2003CA2486564A1 Acetamides and benzamides that are useful in treating sexual dysfunction
12/04/2003CA2486376A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003CA2486187A1 Kinase inhibitors
12/04/2003CA2486113A1 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
12/04/2003CA2486056A1 R-enantiomers of pyranoindole derivatives against hepatitis c
12/04/2003CA2485984A1 Pharmaceutical combination of pde5 inhibitors with ace inhibitors
12/04/2003CA2485972A1 Method for the use of pyranoindole derivatives to treat infection with hepatitis c virus
12/04/2003CA2485166A1 Substituted pyrimidinone and pyridinone compounds
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484656A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003CA2484288A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2483627A1 Mitotic kinesin inhibitors
12/04/2003CA2481394A1 Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol
12/04/2003CA2480756A1 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
12/04/2003CA2480742A1 Tropane compounds
12/04/2003CA2459407A1 Crystalline fluoroquinolone arginine salt form
12/03/2003EP1367057A1 Epothilones C, E and F
1 ... 5255 5256 5257 5258 5259 5260 5261 5262 5263 5264 5265 5266 5267 5268 5269 5270 5271 5272 5273 5274 5275 ... 7860